Evaluating patient perspectives about the acceptability of a novel prognostic gene expression signature for high grade serous ovarian cancer: The OTTA-SPOT study
Participants with ovarian cancer viewed prognostic testing positively. However, successful implementation will require a patient-centred approach that accommodates diverse preferences around how the test is introduced, and results are communicated.
Authors
- Holly E. Evans (ORCID: https://orcid.org/0000-0002-0496-7329)
- Rachel Houweling (ORCID: https://orcid.org/0000-0002-9982-8531)
- Jacinta Frawley
- Claire Elizabeth Wakefield (ORCID: https://orcid.org/0000-0001-7704-7067)
- Michael J. Friedlander (ORCID: https://orcid.org/0000-0003-3090-795X)
- Susan J. Ramus (ORCID: https://orcid.org/0000-0003-0005-7798)
- Lauren Kelada (ORCID: https://orcid.org/0000-0001-9428-8807)
- Yeh Chen Lee (ORCID: https://orcid.org/0000-0003-2009-8263)
- Brittany C. McGill (ORCID: https://orcid.org/0000-0002-2134-2988)
- Jennifer Duggan
- Amber-Marie Firriolo
- Gill Stannard
Institutions
- Royal Hospital for Women (AU)
- Cancer Institute of New South Wales (AU)
Publication Details
- Journal
- Gynecologic Oncology
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1016/j.ygyno.2025.11.023
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Health and Medical Research Council